|
|
Vaccine Detail
|
MEDI0457 |
| Vaccine Information |
- Vaccine Name: MEDI0457
- Target Pathogen: Human Papillomavirus
- Target Disease: HPV infection
- Product Name: MEDI 0457
- Manufacturer: CELLECTRA (Inovio Pharmaceuticals, San Diego, CA)
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: (Hasan et al., 2020)E6 and E7 serve as non self antigens
- E6 HPV 18
gene engineering:
- Type: DNA vaccine construction
- Description: E6 gene is inserted into a DNA vaccine plasmid, which allows the expression of the E6 protein.
- Detailed Gene Information: Click Here.
- E7 Type 16
gene engineering:
- Type: Recombinant protein preparation
- Description: The E7 gene is inserted into a DNA vaccine plasmid, which allows the expression of the E7 protein.
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: (Hasan et al., 2020)MEDI0457 (INO-3112) is a DNA-based vaccine targeting E6 and E7 of HPV-16/18 that is coinjected with an IL-12 plasmid followed by electroporation with the CELLECTRA 5P device. At 2 to 4 weeks after chemoradiation, patients with newly diagnosed stage IB1-IVA (cohort 1) or persistent/recurrent (cohort 2) cervical cancers were treated with 4 immunizations of MEDI0457 every 4 weeks
|
| Host Response |
|
|
| References |
Hasan et al., 2020: Hasan Y, Furtado L, Tergas A, Lee N, Brooks R, McCall A, Golden D, Jolly S, Fleming G, Morrow M, Kraynyak K, Sylvester A, Arif F, Levin M, Schwartz D, Boyer J, Skolnik J, Esser M, Kumar R, Bagarazzi M, Weichselbaum R, Spiotto M. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. International journal of radiation oncology, biology, physics. 2020; 107(3); 487-498. [PubMed: 32151670].
|
|
